Publications by authors named "Gatien Moriceau"

17Publications

High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity.

Anal Chem 2018 03 13;90(5):3299-3306. Epub 2018 Feb 13.

Department of Physics , Virginia Commonwealth University , Richmond , Virginia 23284 , United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.analchem.7b04828DOI Listing
March 2018

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.

Cancer Discov 2018 01 18;8(1):74-93. Epub 2017 Sep 18.

Division of Dermatology, Department of Medicine, University of California, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-17-0682DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456057PMC
January 2018

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma.

Cell Discov 2016 6;2:16028. Epub 2016 Sep 6.

Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Crump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA; California NanoSystems Institute, University of California Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/celldisc.2016.28DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012007PMC
September 2016

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

Cell 2015 Sep;162(6):1271-85

Division of Dermatology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2015.07.061DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821508PMC
September 2015

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.

J Transl Med 2015 Jul 3;13:210. Epub 2015 Jul 3.

Department of Cancer Biology, Beckman Research Institute of City of Hope Cancer Center, Duarte, CA, 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-015-0581-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490757PMC
July 2015

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Cancer Cell 2015 Feb 15;27(2):240-56. Epub 2015 Jan 15.

Division of Dermatology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2014.11.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326539PMC
February 2015

Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.

PLoS One 2014 5;9(3):e90795. Epub 2014 Mar 5.

INSERM, UMR 957, Nantes, France; Université de Nantes, Nantes Atlantique Universités, Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France; Equipe LIGUE Nationale Contre le Cancer 2012, Nantes, France; CHU de Nantes, Nantes, France.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0090795PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944320PMC
November 2014

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Cancer Discov 2014 Jan 21;4(1):69-79. Epub 2013 Nov 21.

1The Division of Dermatology, Department of Medicine, 2Division of Surgical Oncology, Department of Surgery, 3Division of Hematology and Oncology, Department of Medicine, 4Jonsson Comprehensive Cancer Center, 5Department of Molecular and Medical Pharmacology, 6David Geffen School of Medicine, University of California, Los Angeles, California; 7Melanoma Institute of Australia, 8Royal Prince Alfred Hospital, 9Westmead Millennium Institute, and 10Westmead Hospital, University of Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893054PMC
January 2014

MDM4 is a key therapeutic target in cutaneous melanoma.

Nat Med 2012 Aug 22;18(8):1239-47. Epub 2012 Jul 22.

Center for the Biology of Disease, Laboratory for Molecular Cancer Biology, Vlaams Instituut voor Biotechnologie (VIB), Leuven, Belgium; Center for Human Genetics, Katholieke Universiteit (KU) Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.2863DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3744207PMC
August 2012

Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth.

Cancer 2012 Feb 12;118(3):750-60. Epub 2011 Jul 12.

National Institute of Health and Medical Research, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26336DOI Listing
February 2012

mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours.

Curr Med Chem 2007 ;14(13):1381-7

INSERM ERI 7, Faculté de Médecine, 1 rue Gatson Veil, 44035 Nantes cedex 1, F-44035 France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/092986707780831159DOI Listing
September 2007